On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > ORGANIZATION
ORGANIZATION
- Limit CEA Application to Premium-Given Drugs with Big Sales: EFPIA Japan Officials
October 29, 2018
- EFPIA Japan Chief Eyes New Funding Model for Innovative but Pricey Therapies
October 26, 2018
- Japan Wholesaler Chief Suzuki Becomes IFPW Chairman
October 16, 2018
- Asian Consortium for Natural Substance-Based Drug Discovery to Leverage Asian Natural Resources, Japanese Technologies
October 15, 2018
- Japan Drug Industry Vows Further Efforts in Academic Collaboration after Honjo’s Nobel Prize
October 3, 2018
- Generic Use Rate at 72.2% in April-June: JGA
October 1, 2018
- October 2019 “Only Option” for Drug Price Revision Tied to Sales Tax Hike: New FPMAJ Chief
September 25, 2018
- 19 Companies Join JPMA Task Force on Quality Evaluation of Nucleic Acid Therapeutics
September 18, 2018
- Think Tank Led by Ex-Pfizer Japan Chief to Compile Proposal on “100-Year Life” by Year-End
September 5, 2018
- Bayer Yakuhin Chief Prinz Named Vice Chairman of EFPIA Japan
September 3, 2018
- Ex-Pfizer Japan Chief Umeda to Now Helm Advocacy Group
August 29, 2018
- Over Half of Companies Control Supply of Off-Label Information: Ihoken Survey
August 27, 2018
- Regulatory Science Society Says “No” to Off-Label Info Supply by Drug Reps Conditionally OK’ed in Draft MHLW GLs
August 24, 2018
- Drug Wholesalers Post Virtually Flat Sales in FY2017: JPWA
August 10, 2018
- Total No. of Sales Reps Shrinks for 4 Years in a Row at 62,433: Survey
July 27, 2018
- Generic Use Rate at 74.1% in January-March: JGA
July 4, 2018
- Yokokura Wins 4th Term to Lead Japan Medical Association
June 25, 2018
- Expand Exemption Criteria in New Off-Patent Price Cut Rule: Japan Pharma Lobby
June 19, 2018
- Japan Pharma Group Calls for Careful Approach on PMP Deduction for Comparator Drugs
June 19, 2018
- Don’t Make Coverage Decision on CEA, Tweak Prices with Limited Scope: FPMAJ
June 18, 2018
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…